Few studies have compared characteristics between breast cancers in men and women.
To evaluate whether hormone receptor-related gene expression differs between genders, researchers led by Danielle Zakon, MD, and Fraser Symmans, MD, evaluated 321 tumour RNA samples from men with early-stage HR-positive, HER2-negative breast cancer included in the retrospective cohort study of the EORTC 10085/BCG/TBCRC/BIG/NCTN International Male Breast Cancer Programme.
Using the sensitivity to endocrine therapy (SET2,3) index, developed by Symmans, they found gene expression measurements in male patients with breast cancer did not differ from those of female patients.
SET2,3 was prognostic for overall survival in male breast cancer and suggested that chemotherapy may improve the poor prognosis for men with breast cancer and a low SET2,3 index score.
The poster will be presented on December 7.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.